Nevro Corp (NASDAQ:NVRO) reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $100.33 and last traded at $99.86, with a volume of 444,602 shares changing hands. The stock had previously closed at $97.96.

Several equities research analysts have recently issued reports on NVRO shares. Morgan Stanley reiterated a “buy” rating and set a $86.00 price objective on shares of Nevro Corp in a research report on Wednesday, June 29th. Wells Fargo & Co. started coverage on shares of Nevro Corp in a report on Tuesday, July 12th. They issued an “outperform” rating for the company. William Blair started coverage on shares of Nevro Corp in a report on Tuesday, July 19th. They issued an “outperform” rating for the company. Leerink Swann reissued a “buy” rating on shares of Nevro Corp in a report on Monday, June 6th. Finally, Piper Jaffray Cos. started coverage on shares of Nevro Corp in a report on Friday, July 22nd. They issued an “overweight” rating and a $98.00 target price for the company. Ten investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average price target of $102.43.

The stock’s market capitalization is $2.79 billion. The company has a 50-day moving average of $85.27 and a 200-day moving average of $69.07.

Nevro Corp (NASDAQ:NVRO) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.31) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.16. The company earned $55.40 million during the quarter, compared to analysts’ expectations of $45.11 million. The business’s revenue was up 385.5% on a year-over-year basis. On average, equities research analysts anticipate that Nevro Corp will post ($1.43) EPS for the current fiscal year.

In other news, Director Wilfred E. Jaeger sold 155,160 shares of the company’s stock in a transaction that occurred on Wednesday, August 17th. The stock was sold at an average price of $97.31, for a total transaction of $15,098,619.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Doug Alleavitch sold 500 shares of the company’s stock in a transaction that occurred on Wednesday, June 1st. The stock was sold at an average price of $72.00, for a total value of $36,000.00. Following the transaction, the vice president now directly owns 10,961 shares of the company’s stock, valued at $789,192. The disclosure for this sale can be found here.

Nevro Corp. is a medical device company. The Company has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.